LIPELLA PHARMACEUTICAL

Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus

24 9月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Lipella Pharmaceuticals to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York

27 8月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research

22 8月 2024 04:00:00 条件 Nasdaq GlobeNewswire

Lipella Pharmaceuticals Unveils Advanced Bladder Imaging Technique at ICICJ Conference

21 8月 2024 04:00:00 条件 Nasdaq GlobeNewswire

Lipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical Trial

12 8月 2024 04:00:00 条件 Nasdaq GlobeNewswire

Lipella Pharmaceuticals Announces Closing of $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules

01 8月 2024 15:05:00 条件 Nasdaq GlobeNewswire

Lipella Pharmaceuticals Announces $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules

01 8月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Lipella Pharmaceuticals Initiates Phase 2a Trial for LP-310 in Oral Lichen Planus, Enrolls First Patients

29 7月 2024 04:00:00 条件 Nasdaq GlobeNewswire

Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus

31 5月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Lipella Pharmaceuticals Announces Abstract Publication at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

29 5月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b

21 5月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise

17 4月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024

05 4月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis

03 4月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline

05 3月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference

20 2月 2024 07:00:48 条件 Nasdaq GlobeNewswire

Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished

20 12月 2023 07:00:00 条件 Nasdaq GlobeNewswire